| Design and operation of a continuous integrated monoclonal antibody production process F Steinebach, N Ulmer, M Wolf, L Decker, V Schneider, R Wälchli, D Karst, ... Biotechnology Progress 33 (5), 1303-1313, 2017 | 108 | 2017 |
| Process‐wide control and automation of an integrated continuous manufacturing platform for antibodies F Feidl, S Vogg, M Wolf, M Podobnik, C Ruggeri, N Ulmer, R Wälchli, ... Biotechnology and Bioengineering 117 (5), 1367-1380, 2020 | 85 | 2020 |
| Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization R Wälchli, M Ressurreição, S Vogg, F Feidl, J Angelo, X Xu, S Ghose, ... Biotechnology and bioengineering 117 (3), 687-700, 2020 | 41 | 2020 |
| Accelerated aggregation studies of monoclonal antibodies: considerations for storage stability R Wälchli, PJ Vermeire, J Massant, P Arosio Journal of pharmaceutical sciences 109 (1), 595-602, 2020 | 40 | 2020 |
| Relationship of PEG-induced precipitation with protein-protein interactions and aggregation rates of high concentration mAb formulations at 5 C R Wälchli, F Fanizzi, J Massant, P Arosio European Journal of Pharmaceutics and Biopharmaceutics 151, 53-60, 2020 | 18 | 2020 |
| Adsorption Behavior of Charge Isoforms of Monoclonal Antibodies on Strong Cation Exchangers F Steinebach, R Wälchli, D Pfister, M Morbidelli Biotechnology journal 12 (12), 1700123, 2017 | 5 | 2017 |
| Stability of Therapeutic Antibodies in Manufacturing and Storage R Wälchli ETH Zurich, 2019 | | 2019 |
Moritz WolfETH Zürich在 chem.ethz.ch 的电子邮件经过验证
